← Eichor
Study identifier: NCT05942625 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects

Condition: IgA Nephropathy · Focal Segmental Glomerulosclerosis  ·  Sponsor: Hansoh BioMedical R&D Company

PhasePhase 1
Planned participants84
Who can joinAll sexes, 18 Years to 45 Years
Healthy volunteersYes

About this study

The purpose of this first in human study is to evaluate the safety, tolerability, pharmacokinetics (PK),and pharmacodynamics (PD) of HS-10390 in healthy subjects.

This description comes directly from the study's public registry record.

Talk to the study team

Bicheng Liu  ·  18001580838  ·  liubc64@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Zhongda Hospital, Affiliated to Southeast UniversityNanjing, Jiangsu, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05942625